|Joseph D. Spahn, Stanley J. Szefler*|
Immunopharmacology Laboratory, Division of Allergy and Immunology, Department of Pediatrics, Nationall Jewish Medical and Research Center, and Department of Pediatrics, University of Colorado Health Sciences Center
*Division of Clinical Pharmacology, Dep
Recently, a concerted effort has been made to reverse the trend of increasing asthma mortality and morbidity. One additional strategy might be to recognize patients at risk for persistent asthma and to intervene early. This review summarizes new information on asthma pathogenesis that has helped shape a new direction in managing childhood asthma. At the core is the recognition that asthma is a chronic inflammatory disease. Subsequently, inhaled steroids, the most potent anti-inflammatory asthma medications, have emerged as the cornerstone of the management of persistent asthma. The recent report of the National Heart, Lung, and Blood Institute’s Childhood Asthma Management Program provides a comprehensive “profile of performance” for 3 treatment choices for the management of persistent asthma. This study answers questions regarding the benefits and shortcomings of the medications evaluated and prompts a closer evaluation of the long-term effects of other treatment strategies, including medications currently being developed. Although intervention with inhaled steroids offers new opportunities to control the development of asthma, one must be cognizant of potential risks in early and long-term therapeutic intervention. This review provides a perspective on our present knowledge, the rationale for early intervention, and opportunity for more aggressive therapy, as well as speculation on how ongoing clinical research will continue to play a role in advancing asthma care and moving toward a “cure” for this life-threatening disease.
Alergia Astma Immunologia, 2002, 8(2), 79-90
keywords: leki rozszerzające oskrzela, astma wieku dziecięcego, Program Leczenia Astmy u Dzieci, kromoglikan sodu, wziewne sterydy, przewlekłe leczenie przeciwzapalne, teofilina, Bronchodilators, childhood asthma, Childhood Asthma Management Program, cromolyn, inha
pages: from 79 to 90
|estimated time of download (312 kB)|